|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2022
As of Oct 31, 2022
|
Q3 FY2021
As of Oct 31, 2021
|
Q3 FY2020
As of Nov 2, 2020
|
Q3 FY2019
As of Oct 31, 2019
|
Q3 FY2018
As of Aug 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | ||||||||||
| Accounts receivable (Note 18) | ||||||||||
| Biological assets (Note 3) | ||||||||||
| Inventory (Note 4) | ||||||||||
| Prepaid expenses and other assets | ||||||||||
| Notes receivable (Note 6.2) | ||||||||||
| Total current assets | ||||||||||
| Property and equipment (Note 8) | ||||||||||
| Other investments | ||||||||||
| Notes receivable (Notes 6.2.1 and 6.2.2) | ||||||||||
| ASSETS | ||||||||||
| Current assets | ||||||||||
| Cash and cash equivalents | ||||||||||
| Accounts receivable, net (Note 4) | ||||||||||
| Inventory (Note 5) | ||||||||||
| Prepaid expenses | ||||||||||
| Derivative asset (Note 12) | ||||||||||
| Current portion of notes receivable (Note 8) | ||||||||||
| Total current assets | ||||||||||
| Other long-term assets | ||||||||||
| Warrants asset (Note 6) | ||||||||||
| Intangible assets and goodwill (Note 9) | ||||||||||
| Deferred tax assets (Note 20) | ||||||||||
| TOTAL ASSETS | ||||||||||
| Accounts payable and accrued liabilities | ||||||||||
| Current portion of lease liabilities (Note 7) | ||||||||||
| Current portion of long-term debt (Note 10) | ||||||||||
| Other investments (Note 7) | ||||||||||
| Notes receivable (Note 8) | ||||||||||
| Lease receivable (Note 11) | ||||||||||
| Lease receivable | ||||||||||
| Property and equipment, net (Note 9) | ||||||||||
| Right of use assets (Note 10) | ||||||||||
| Deferred tax asset | ||||||||||
| Intangible assets | ||||||||||
| TOTAL ASSETS | ||||||||||
| LIABILITIES | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable and accrued liabilities | ||||||||||
| Current portion of operating lease liabilities (Note 10) | ||||||||||
| Current portion of finance lease liabilities (Note 10) | ||||||||||
| Current portion of long-term debt (Note 11) | ||||||||||
| Convertible debentures (Note 15) | ||||||||||
| Current portion of business acquisition consideration payable | ||||||||||
| Derivative liability | ||||||||||
| Warrant liabilities (Note 12) | ||||||||||
| Income tax payable | ||||||||||
| Total current liabilities | ||||||||||
| Operating lease liabilities (Note 10) | ||||||||||
| Finance lease liabilities (Note 10) | ||||||||||
| Long-term debt (Note 11) | ||||||||||
| Consideration payable on business acquisitions, net of discounts and current portion (Note 14) | ||||||||||
| Business acquisition consideration payable | ||||||||||
| Interest payable (Note 14) | ||||||||||
| Derivative liability (Notes 11.1.1, 11.2 and 11.2.1) | ||||||||||
| Lease liabilities | ||||||||||
| Long-term debt (Note 10) | ||||||||||
| Uncertain tax position liability | ||||||||||
| Convertible debentures (Notes 11.1, 11.2 and 11.2.1) | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Share capital (Note 12) | ||||||||||
| Contributed surplus (Notes 13 and 14) | ||||||||||
| Accumulated other comprehensive loss | ||||||||||
| Accumulated deficit | ||||||||||
| Equity attributable to shareholders | ||||||||||
| Non-controlling interest (Note 23) | ||||||||||
| TOTAL EQUITY | ||||||||||
| TOTAL LIABILITIES AND EQUITY | ||||||||||
| Other non-current liabilities | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Subordinate voting common shares, convertible into multiple voting common shares, no par value; unlimited shares authorized; 249,938,980 and 249,738,980 shares issued and outstanding as at June 30, 2026 and December 31, 2025, respectively | ||||||||||
| Accumulated other comprehensive loss | ||||||||||
| Accumulated deficit | ||||||||||
| Equity attributable to shareholders | ||||||||||
| Non-controlling interests (Note 22) | ||||||||||
| TOTAL SHAREHOLDERS’ EQUITY | ||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
Loading...